An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...

(NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has expanded approval of TALZENNA ® (talazoparib ...

Johnson & Johnson (J&J) said that an early-stage trial of JNJ-6143 (previously HLD-0915) found that the novel oral Regulated ...

Johnson & Johnson (NYSE:JNJ) has presented Phase 1 clinical trial results for JNJ-6143, an investigational oral treatment for advanced prostate cancer, at the European Society for Medical Oncology ...

Oct 24 (Reuters) - Johnson & Johnson on Saturday said its experimental once-daily oral prostate cancer drug caused tumors to ...

JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted ...

New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ...

Johnson & Johnson announced promising Phase 1 results for JNJ-6143 (formerly HLD-0915), an investigational once-daily oral Regulated Induced Proximity Targeting Chimera (RIPTAC) small molecule, in ...

In preclinical castration-resistant prostate cancer models, combining B7-H3 blockade with the MEK inhibitor trametinib ...

Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and an assistant professor at the University of Central Florida’s College of Medicine. “How long do I have to live ?” When I ...

Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (64.1%): drugs i ...

Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus androgen deprivation therapy (ADT), given ...